

Bibliografia trattamento farmacologico DD

1. Brown, S. E., Carmody, T. J., Schmitz, J. M., et al. (2009) A randomized, doubleblind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. *Alcoholism: Clinical and Experimental Research*, 33, 1863–1869.
2. Green, A. I., Noordsy, D. L., Brunette, M. F., et al. (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. *Journal of Substance Abuse Treatment*, 34, 61–71.
3. Hjorthoj, C., Fohlmann, A. & Norentoft, M. (2009) Treatment of cannabis use disorders in people with schizophrenia spectrum disorders: a systematic review. *Addictive Behaviours*, 34, 846–851.
4. Kemp, D. E., Gao, K., Ganocy, S. J., et al. (2009) A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. *Journal of Clinical Psychiatry*, 70, 113–121.
5. Mills, K. L., Deady, M., Proudfoot, H., et al. (2009) *Guidelines on the Management of Co-occurring Alcohol and Other Drug and Mental Health Conditions in Alcohol and Other Drug Treatment Settings*. Sydney: University of New South Wales.
6. Nejtek, V. A., Avila, M., Chen, L. A., et al. (2008) Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. *Journal of Clinical Psychiatry*, 69, 1257–1266.
7. San, L., Arranz, B. & Martinez-Raga, J. (2007) Antipsychotic drug treatment of schizophrenia patients with substance abuse disorder. *European Addiction Research*, 13, 230–243.
8. Smelson, D. A., Dixon, K., Craig, T., et al. (2008) Pharmacological treatment of schizophrenia and co-occurring substance use disorders. *CNS Drugs*, 22, 903–916.
9. Van Nimwegen, L. J., de Haan, L., van Beveren, N. J., et al. (2008) Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. *Canadian Journal of Psychiatry*, 53, 400–405.